Skip to Content
Merck

06863

Glycoursodeoxycholic acid

≥96.0% (TLC)

Synonym(s):

N-(3α,7β-Dihydroxy-5β-cholan-24-oyl)glycine, N-[(3α,5β,7β)-3,7-Dihydroxy-24-oxocholan-24-yl]glycine, GUDCA, Glycylursodeoxycholic acid, Ursodeoxycholylglycine

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C26H43NO5
CAS Number:
Molecular Weight:
449.62
UNSPSC Code:
12161900
PubChem Substance ID:
NACRES:
NA.25
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

GHCZAUBVMUEKKP-XROMFQGDSA-N

InChI

1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

biological source

synthetic

assay

≥96.0% (TLC)

form

powder

functional group

carboxylic acid

Quality Level

Looking for similar products? Visit Product Comparison Guide

Application


  • Glycoursodeoxycholic Acid Alleviates Arterial Thrombosis via Suppressing Diacylglycerol Kinases Activity in Platelet.: Highlights the therapeutic potential of Glycoursodeoxycholic acid in alleviating arterial thrombosis by inhibiting diacylglycerol kinase activity in platelets (Yang et al., 2024).

Biochem/physiol Actions

Secondary bile acid derived from acyl glycine. Glycoursodeoxycholic Acid (GUDCA) is reported to have cytoprotective and anti-inflammatory effects.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jingyu Yan et al.
Scientific reports, 7(1), 4211-4211 (2017-06-25)
Cholestasis is a clinical disorder defined as an impairment of bile flow, and that leads to toxic bile acid (BA) accumulation in hepatocytes. Here, we investigated the hepatoprotective effect of Yinchenhaotang (YCHT), a well-known formulae for the treatment of jaundice
Kazuya Maeda et al.
Molecular pharmaceutics, 3(1), 70-77 (2006-05-12)
Ursodeoxycholate (UDCA) is widely used for the treatment of cholestatic liver disease. After oral administration, UDCA is absorbed, taken up efficiently by hepatocytes, and conjugated mainly with glycine to form glycoursodeoxycholate (GUDC) or partly with taurine to form tauroursodeoxycholate (TUDC)
Sandra L Silva et al.
Neuropharmacology, 62(7), 2398-2408 (2012-03-01)
Neuronal oxidative damage and cell death by unconjugated bilirubin (UCB) showed to be mediated by overstimulation of glutamate receptors and nitric oxide (NO) production, which was abrogated by the bile acid glycoursodeoxycholic acid (GUDCA). Microglia, a crucial mediator of CNS
Viktoriia Starokozhko et al.
Archives of toxicology, 91(10), 3403-3413 (2017-04-10)
Drug-induced cholestasis (DIC) is one of the leading manifestations of drug-induced liver injury (DILI). As the underlying mechanisms for DIC are not fully known and specific and predictive biomarkers and pre-clinical models are lacking, the occurrence of DIC is often
M J Perez et al.
British journal of pharmacology, 162(8), 1686-1699 (2010-12-24)
Mitochondria are involved in the toxicity of several compounds, retro-control of gene expression and apoptosis activation. The effect of mitochondrial genome (mtDNA) depletion on changes in ABC transporter protein expression in response to bile acids and paracetamol was investigated. Hepa

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service